Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

A Phase 1, Single-Center, Open-Label, Induction Dose Study of ABP-700 in Healthy, Adult Subjects

- candidate number23339
- NTR NumberNTR5442
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR5-nov-2015
- Secondary IDsANVN-01-05 150322-CS0249
- Public TitleA Phase 1, Single-Center, Open-Label, Induction Dose Study of ABP-700 in Healthy, Adult Subjects
- Scientific TitleA Phase 1, Single-Center, Open-Label, Induction Dose Study of ABP-700 in Healthy, Adult Subjects
- hypothesisēTo assess the safety and tolerability of induction doses of ABP-700 and determine dosing regimens that reliably produce drug induced unconsciousness and the pharmacodynamic conditions necessary for induction of general anesthesia with ABP-700 alone and in combination with fentanyl and midazolam
- Healt Condition(s) or Problem(s) studiedHealthy volunteers
- Inclusion criteria1. Healthy, adult, men and women, 18-55 years of age, inclusive at screening.
2. Continuous non-smoker who has not used nicotine-containing products for at least 6 months prior to the first dose.
3. Body Mass Index (BMI) ≥ 17.5 and ≤ 30.0 kg/m2 and a total body weight >50 kg, at screening and check-in.
4. Medically healthy with no clinically significant out of range laboratory findings, vital signs or ECGs, as deemed by the PI.
5. Women of non-childbearing potential, i.e., must have undergone one of the following sterilization procedures at least 6 months prior to the first dose:
a. hysteroscopic sterilization;
b. bilateral tubal ligation or bilateral salpingectomy;
c. hysterectomy;
d. bilateral oophorectomy;
or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and FSH serum levels consistent with postmenopausal status (greater than 30 IU/L) .
6. Women of child bearing potential must agree to use one or more of the following forms of contraception from the time of signing the informed consent form through 90 days following the last administration of study medication: hormonal (i.e., oral, transdermal, implant, or injection); double barrier (i.e., condom, diaphragm with spermicide); intrauterine device (IUD); vasectomized partner (six months minimum); or abstinence.
7. Non-vasectomized men must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days beyond the last dose of study medication. Men who have been vasectomized less than 4 months prior to study start must follow the same restrictions as non-vasectomized men.
8. Men must agree not to donate sperm from the first dose until 90 days after dosing.
9. Obtain a score of I or II using the Modified Mallampati Scoring.
10. Understand the study procedures in the informed consent form(s) (ICF(s)), and be willing and able to comply with the protocol.
11. Agree not to make any public disclosure of personal medical data related to the study or other information related to the study, including posting on any website or social media site (e.g., Facebook, Twitter, etc.).
- Exclusion criteria1. History or presence of significant cardiovascular disease, or cardiovascular disease risk factors, hyperlipidemia, coronary artery disease, or any known genetic pre disposition to cardiac arrhythmia (including long QT syndrome).
2. History or presence of significant pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological (inclusive of any seizure disorder), or psychiatric disease.
3. History of any illness that, in the opinion of the PI, might confound the results of the study or pose an additional risk to the subject by their participation in the study.
4. Surgery within the past 90 days prior to dosing judged by the PI to be clinically relevant.
5. History of febrile illness within 5 days prior to dosing.
6. History or presence of alcoholism, drug abuse or illicit drug use within the past 2 years.
7. History of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men [1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor] within 6 months of screening.
8. Hypersensitivity or idiosyncratic reaction to components of ABP-700 (meglumine and/or sulfobutylether-beta-cyclodextrin), fentanyl, midazolam, egg, egg products, soybeans, soy, or to compounds related to the study medications.
9. History or presence of adrenal insufficiency as defined by serum cortisol level <6 Ķg/dL at screening.
10. Women who are pregnant or lactating.
11. Positive results for the urine drug screen and alcohol breath test at screening or check-in (Day -1).
12. Positive urine cotinine at screening.
13. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV).
14. Single 12-lead ECG demonstrating QTcF interval >450 msec at screening.
15. Unable to refrain from or anticipates the use of any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning approximately 14 days prior to dosing and throughout the study, with the exception of oral contraceptives. Ibuprofen (1.2 g per 24 hour period) may be permitted during the study at the PIís discretion.
16. Use of any drugs known to be hormonal replacement therapy, inducers of cytochrome P450 (CYP) enzymes, including St. Johnís Wort, within 28 days prior to the first dose of study medication. Appropriate sources will be consulted by the PI to confirm lack of PK/PD interaction with study medication(s).
17. Have a diet incompatible with the clinic diet, in the opinion of the PI, within the 28 days prior to the first dose of study medication(s), and throughout the study.
18. Blood donation or significant blood loss within 90 days prior to dosing.
19. Plasma donation within 7 days prior to dosing.
20. Participation in another clinical trial within 90 days prior to dosing. The 90-day window will be derived from the date of the last study procedure (such as last blood collection or dosing) in the previous study to Day 1 of the current study.
21. Subjects who previously received ABP-700.
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingNone
- controlNot applicable
- groupParallel
- Type2 or more arms, non-randomized
- Studytypeintervention
- planned startdate 9-nov-2015
- planned closingdate
- Target number of participants80
- InterventionsABP-700, fentanyl, midazolam
- Primary outcomeTo assess the safety and tolerability of induction doses of ABP-700. To determine dosing regimens that reliably produce drug induced unconsciousness and the pharmacodynamic conditions necessary for induction of general anesthesia with ABP-700 alone and in combination with fentanyl and midazolam.
- Secondary outcomeTo characterize the pharmacokinetics (PK) of ABP-700 and its primary metabolite (CPM-acid).
To assess the pharmacodynamics (PD) of ABP-700.
To investigate dose response and PK/PD relationships.
- TimepointsScreening (-28 days), Check-in (-1 day), Study Days (1-2), Follow-up (day 4-6)
- Trial web site
- statusopen: patient inclusion
- Sponsor/Initiator The Medicines Company
- Funding
(Source(s) of Monetary or Material Support)
The Medicines Company
- Publications
- Brief summaryABP-700 is an intravenous (IV) sedative-hypnotic agent currently in Phase I clinical development and is being developed the induction of general anesthesia and procedural sedation in patients undergoing diagnostic or therapeutic procedures.
The highly dynamic nature of surgical and procedural intervention, as well as the short duration of these procedures, demands the development of potent yet rapidly reversible anesthetic agents. Ideally, the pharmacokinetics (PK) and pharmacodynamics (PD) of these anesthetic agents should be better matched to the procedures being performed. In general, currently used agents are either too long-acting or not easily titratable to the desired level of effect. The result is a clear unmet need for more effective drugs with a higher therapeutic index that exhibit a predictable PK/PD relationship and allow precisely tailored control of sedation and anesthesia. Newer sedative/anesthetic drugs that are potent, have minimal hemodynamic effects and reduced toxicities, and have a PK/PD profile that enables them to be more readily titratable are highly desired to meet these evolving patient and healthcare needs.
ABP-700 is a newly developed, potent, positive allosteric modulator of the GABAA receptor. Its mechanism of action is via potentiation of GABAA receptor activation producing its sedative and anesthetic effects. ABP-700 contains an ester bond that was precisely designed to undergo rapid hydrolysis in the body by nonspecific tissue esterases that produce an inactive carboxylic acid metabolite. This chemical approach has been used previously in approved drugs such as remifentanil, esmolol, and clevidipine, resulting in rapid inactivation of pharmacologic activity and a unique PK profile.
- Main changes (audit trail)
- RECORD5-nov-2015 - 22-nov-2015

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar